Merck, ODAC Mostly Like US FDA's Point-Counterpoint Briefing Document

 
• By Derrick Gingery
  
StacksOfPapers_1200x675
The point-counterpoint format is intent on reducing duplication in US FDA advisory committee briefing documents. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers